Clinical Overview
Sodium oxybate is a central nervous system depressant indicated for cataplexy and excessive daytime sleepiness in narcolepsy. It is the sodium salt of gamma-hydroxybutyrate (GHB) and is available only through a restricted distribution program due to its potential for abuse and serious safety risks. Despite its abuse potential, it is highly effective for narcolepsy symptoms when used appropriately.
Primary Clinical Applications
Sodium oxybate is indicated for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy. It is particularly effective for cataplexy (sudden loss of muscle tone triggered by emotions) and can significantly improve the quality of nighttime sleep, leading to reduced daytime sleepiness.
Mechanism and Clinical Benefits
Sodium oxybate acts as a GABA-B receptor agonist, promoting deep, restorative sleep and reducing sleep fragmentation. This improved sleep quality leads to better daytime alertness and reduced cataplexy episodes. The medication consolidates sleep and increases slow-wave sleep, which is often deficient in narcolepsy patients.
Safety and Distribution
Due to its potential for abuse, respiratory depression, and use as a date-rape drug, sodium oxybate is available only through a restricted REMS program. Patients must be enrolled in the program, and the medication is shipped directly to patients from a central pharmacy. Strict monitoring and patient education are required throughout treatment.
Prescribing Information
Dosing & Administration
Narcolepsy – Adults:
- Initial: 4.5 g nightly (2.25 g x 2 doses)
- Titration: Increase by 1.5 g nightly (0.75 g per dose) weekly
- Range: 6-9 g nightly (3-4.5 g x 2 doses)
- Maximum: 9 g nightly
Dosing Schedule:
- First dose: At bedtime while in bed
- Second dose: 2.5-4 hours after first dose
- Patient must set alarm for second dose
Administration:
- Dilute each dose in 60 mL (1/4 cup) of water
- Take on empty stomach (at least 2 hours after eating)
- Remain in bed after taking each dose
- Prepare both doses before bedtime
Indications
- Treatment of cataplexy in patients with narcolepsy
- Treatment of excessive daytime sleepiness in patients with narcolepsy
Contraindications
- Hypersensitivity to sodium oxybate
- Concomitant use with sedative hypnotics or alcohol
- Patients with succinic semialdehyde dehydrogenase deficiency
Warnings & Precautions
- Boxed Warning: CNS depressant with abuse potential; respiratory depression and death risk
- REMS program: Available only through restricted distribution
- Respiratory depression: Life-threatening risk, especially with alcohol or other CNS depressants
- Abuse potential: Schedule III controlled substance
- Complex sleep behaviors: Sleepwalking, sleep-driving reported
- Depression and suicidality: Monitor for mood changes
- Sodium content: Significant sodium load (Xyrem contains 0.5-1.6 g sodium per night)
Drug Interactions
- CNS depressants: Contraindicated – life-threatening respiratory depression
- Alcohol: Contraindicated – potentially fatal interaction
- Divalproex sodium: Increases sodium oxybate levels
Adverse Reactions
Common (≥5%):
- Nausea, dizziness, vomiting, somnolence
- Enuresis (bedwetting), tremor, sleepwalking
Serious:
- Respiratory depression, coma, death
- Abuse, dependence, withdrawal
Special Populations
- Hepatic Impairment: Reduce dose by 50% initially
- Renal Impairment: Use caution, monitor closely
- Heart Failure: Monitor sodium intake (Xyrem has high sodium content)
- REMS Program: All patients must be enrolled with strict monitoring
- Pregnancy: Category B – use only if clearly needed
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
